Pediatric Pulmonary Vascular Disease

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient

David Procaccini, Dennis Delany, Abigail Self, Patricia Lawrence Kane, John D. CoulsonJohns Hopkins HospitalUnited States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2023; 28: 102-107DOI: 10.5863/1551-6776-28.1.102 AbstractWe report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his […]

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient Read More »

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

Thomas R. Fleming, Christine E. Garnett, Laurie S. Conklin, Solange Corriol‑Rohou, Sudharshan Hariharan, Daphne Hsu, Guenther Mueller‑Velten, Yeruk Mulugeta, Ronald Portman, Mark D. Rothmann, Norman L. Stockbridge, Simon Wandel, Jialu Zhang, Lynne YaoUniversity of Washington. U.S. Food and Drug Administration. Janssen Research and Development. AstraZeneca. Children’s Hospital at Montefiore and Albert Einstein College of Medicine. Novartis Pharma AG and Novartis Pharmaceuticals.United States Therapeutic Innovation and Regulatory ScienceTher Innov Regul Sci 2023; 57: 109-120DOI: 10.1007/s43441-022-00445-6 AbstractEven with recent substantive improvements in health care in pediatric populations, considerable need remains

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation Read More »

Pulmonary Vein Atresia: Feasibility of Initial Recanalization Attempts with Subsequent Follow-up

Varun Aggarwal, Gary E. Stapleton, Lindsay F. Eilers, Srinath Gowda, Manish Bansal, Athar M. Qureshi, Melissa K. Webb, Asra Khan, Henri JustinoBaylor College of Medicine and Texas Children’s HospitalUnited States Current Problems in CardiologyCurr Probl Cardiol 2023; 48: DOI: 10.1016/j.cpcardiol.2022.101463 AbstractPulmonary vein atresia (PVA) may lead to pulmonary hypertension, cardiac failure, and death. Transcatheter or surgical treatments have rarely been offered to this population because of perceived poor outcomes. We describe single center

Pulmonary Vein Atresia: Feasibility of Initial Recanalization Attempts with Subsequent Follow-up Read More »

NT-proBNP and Zlog-transformed NT-proBNP values predict extubation failure in critically ill neonates with pulmonary hypertension and ventricular dysfunction

Lukas Schroeder, Manuel Kuelshammer, Ramona Dolsheid-Pommerich, Stefan Holdenrieder, Andreas Mueller, Florian KipfmuellerUniversity Children’s Hospital Bonn. University Hospital Bonn. Technical University Munich.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 253-261DOI: 10.1002/ppul.26193 AbstractObjectives: Critically ill neonates with a history of pulmonary hypertension (PH) or ventricular dysfunction are at risk to experience an extubation failure (EF) after liberation from mechanical ventilation (MV).

NT-proBNP and Zlog-transformed NT-proBNP values predict extubation failure in critically ill neonates with pulmonary hypertension and ventricular dysfunction Read More »

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis

Jefferson Antonio Buendia, Diana Guerrero Patino, Erika Fernanda LindarteUniversity of Antioquia.Columbia Pediatric PulmonologyPediatr Pulmonol 2023; DOI: 10.1002/ppul.26361 AbstractIntroduction: Despite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with Pulmonary arterial hypertension. This study aims to determine the cost-utility of ambrisentan regarding

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis Read More »

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension

Hythem Nawaytou, Nancy K. Hills, Ronald I. ClymanUniversity of California San Francisco.United States Pediatric ResearchPediatr Res 2023; DOI: 10.1038/s41390-023-02522-4 AbstractBackground: The aim of the study was to determine whether prolonged exposure to a moderate/large patent ductus arteriosus left-to-right shunt (PDA) increases the risk of late (beyond 36 weeks) pulmonary hypertension (BPD-PH) and pulmonary vascular disease (BPD-PVD) during

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension Read More »

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study

Azza Tantawy, Nayera El‑Sherif, Sara Makkeyah, Nahed Salah Eldeen, Noura Bahaa El‑Din Farghal, Nanies Soliman, Fatma S. E. EbeidAin Shams University.Egypt Annals of HematologyAnn Hematol 2023; 102: 271-281DOI: 10.1007/s00277-023-05099-4 AbstractSleep disordered breathing (SDB) is a common underdiagnosed sequela of sickle cell disease (SCD) that has been linked to the frequency of vaso-occlusive crises. To determine the frequency of SDB in children with SCD and its association to SCD-related

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study Read More »

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension

Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, Dorina van der Mey, Gagriela Wirsching, Yang Zhang, Henk-Jan Drenth, Anne Keunecke, Esmée Vendel, Soundos SalehBayer AG. LAP&P Consultants.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 908-917DOI: 10.1002/ppul.26277 AbstractBackground: The PATENT-CHILD study investigated riociguat in children aged ≥ 6 to <18 years with pulmonary arterial hypertension (PAH) treated with tablets or an

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension Read More »

A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients

David Edward Youssef, Konstantin Averin, Susan Richards, Catherine Sheppard, Cameron Seaman, Matthew Pietrosanu and Angela BatesUniversity of Alberta and Stollery Children’s Hospital. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.Canada and United States Frontiers in PediatricsFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1073336 AbstractIntroduction: The clinical deterioration commonly experienced by pediatric patients with pulmonary arterial hypertension (PAH) has

A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients Read More »

Scroll to Top